Zeev Estrov Selected Research

Idarubicin (4 Demethoxydaunorubicin)

9/2019	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
1/2018	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
1/2018	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
1/2018	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
11/2017	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
1/2017	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
1/2017	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
11/2013	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
3/2011	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
4/2010	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zeev Estrov Research Topics

Disease

66	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2002
59	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 06/2002
45	Neoplasms (Cancer) 01/2021 - 06/2003
34	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 06/2002
34	Leukemia 01/2021 - 06/2002
19	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2020 - 06/2002
18	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 06/2002
17	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 02/2010
10	Hematologic Neoplasms (Hematological Malignancy) 12/2017 - 01/2002
9	Philadelphia Chromosome 02/2018 - 04/2007
9	Polycythemia Vera 04/2017 - 02/2008
8	Blast Crisis (Blast Phase) 11/2020 - 02/2005
7	Exanthema (Rash) 01/2021 - 06/2013
7	Splenomegaly 01/2021 - 06/2010
7	Infections 09/2018 - 04/2010
6	Residual Neoplasm 11/2019 - 01/2004
5	Fibrosis (Cirrhosis) 01/2022 - 01/2016
5	Fatigue 01/2021 - 01/2003
5	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 06/2002
5	Disease Progression 01/2019 - 10/2012
4	Neutropenia 01/2021 - 04/2007
4	Thrombocytopenia (Thrombopenia) 01/2021 - 06/2013
4	Essential Thrombocythemia 08/2013 - 01/2003
3	Hypertension (High Blood Pressure) 01/2019 - 07/2006
3	Aplastic Anemia (Anemia, Hypoplastic) 11/2018 - 05/2012
3	Cytopenia 10/2018 - 02/2010
3	Nausea 09/2018 - 02/2015
3	Diarrhea 01/2018 - 10/2008
3	Anemia 01/2018 - 06/2013
3	Acute Promyelocytic Leukemia 01/2017 - 02/2009
3	Pathologic Complete Response 12/2015 - 01/2003
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2019
2	Inflammation (Inflammations) 01/2021 - 12/2013
2	Pleural Effusion (Pleural Effusions) 01/2020 - 01/2018
2	Hyperbilirubinemia 11/2017 - 10/2008

Drug/Important Bio-Agent (IBA)

21	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 02/2005
17	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2003
14	ibrutinibIBA 12/2021 - 03/2015
13	ruxolitinibIBA 01/2021 - 09/2010
12	Rituximab (Mabthera)FDA Link 12/2021 - 01/2008
12	CytokinesIBA 01/2021 - 08/2002
12	Imatinib Mesylate (Gleevec)FDA Link 11/2019 - 02/2003
11	fludarabineIBA 12/2021 - 12/2005
11	Clofarabine (Clolar)FDA Link 01/2021 - 02/2005
10	Lenalidomide (CC 5013)FDA Link 01/2021 - 06/2008
10	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 09/2019 - 04/2010
10	Phosphotransferases (Kinase)IBA 07/2014 - 06/2003
9	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 10/2007
9	Tyrosine Kinase InhibitorsIBA 01/2019 - 12/2003
8	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 03/2015
8	Dasatinib (BMS 354825)FDA Link 11/2020 - 05/2009
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 08/2011
7	venetoclaxIBA 08/2021 - 12/2018
7	Decitabine FDA Link 01/2021 - 11/2006
6	Indicators and Reagents (Reagents)IBA 07/2018 - 02/2010
6	MicroRNAs (MicroRNA)IBA 01/2016 - 03/2008
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2002
5	Transaminases (Aminotransferases)IBA 01/2020 - 10/2008
5	NF-kappa B (NF-kB)IBA 10/2018 - 08/2003
5	Histone Deacetylase InhibitorsIBA 12/2017 - 11/2006
4	Pharmaceutical PreparationsIBA 10/2018 - 07/2006
4	Janus Kinase 2IBA 11/2017 - 06/2008
4	Biological ProductsIBA 05/2016 - 08/2002
4	Vincristine (Oncovin)FDA LinkGeneric 02/2016 - 02/2015
4	NucleosidesIBA 11/2013 - 02/2005
4	Caspase 3 (Caspase-3)IBA 05/2009 - 06/2002
3	nilotinib FDA Link 01/2020 - 09/2005
3	BilirubinIBA 01/2020 - 02/2015
3	HomoharringtonineIBA 01/2019 - 01/2007
3	Hemoglobins (Hemoglobin)IBA 07/2018 - 06/2010
3	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 02/2008
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2018 - 08/2006
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017 - 10/2007
3	fms-Like Tyrosine Kinase 3IBA 11/2016 - 04/2006
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016 - 08/2002
3	DNA (Deoxyribonucleic Acid)IBA 06/2014 - 09/2010
3	RNA (Ribonucleic Acid)IBA 12/2011 - 04/2010
3	azaspiraneIBA 10/2011 - 01/2007
3	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2011 - 03/2008
3	Transcription Factors (Transcription Factor)IBA 12/2007 - 08/2003
2	Reticulin (Reticular Fiber)IBA 01/2022 - 10/2018
2	ponatinibIBA 01/2019 - 11/2015
2	Nonesterified Fatty Acids (NEFA)IBA 11/2018 - 01/2016
2	Purine NucleosidesIBA 01/2018 - 11/2017
2	SB939 compoundIBA 12/2017 - 09/2012
2	Tyrosine (L-Tyrosine)FDA Link 11/2017 - 04/2010
2	CalreticulinIBA 10/2017 - 01/2017
2	Core Binding Factors (Core-Binding Factor)IBA 09/2017 - 05/2009
2	peginterferon alfa-2a (Pegasys)FDA Link 04/2017 - 11/2009
2	Arsenic Trioxide (Trisenox)FDA Link 01/2017 - 02/2009
2	Janus KinasesIBA 01/2017 - 02/2008
2	Serine (L-Serine)FDA Link 01/2017 - 04/2010
2	Gemtuzumab (Mylotarg)FDA Link 01/2017 - 02/2009

Therapy/Procedure

55	Therapeutics 01/2022 - 01/2003
21	Drug Therapy (Chemotherapy) 01/2021 - 01/2004
5	Stem Cell Transplantation 09/2019 - 06/2011
4	Salvage Therapy 01/2021 - 10/2008
3	Induction Chemotherapy 09/2019 - 06/2011
2	Immunotherapy 01/2022 - 11/2013
2	Drug Tapering 01/2020 - 01/2018